Clinical Trial Update: Zevalin Twice in Aggressive Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of Zevalin (ibritumomab tiuxetan) in aggressive diffuse large B-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: TERMINATED